News
Please check back frequently for company news and new peer-reviewed scientific publications featuring the Vala platform.
2022
February 2022
Conference: Vala Sciences will be at SLAS 2022 in Boston!
Patrick M. McDonough, Ph.D., Vala’s Chief Research Officer, will give a podium presentation in the Advanced Imaging and High Content Assays session on Monday, February 7 at 10:30am. Presentation title: High-content analysis and Kinetic Image Cytometry identify toxic and epigenotoxic effects of HIV antiretrovirals on human iPSC-neurons and neural precursor cells Read more about this research here.
Jeffrey H. Price, M.D., Ph.D., Vala’s Founder, President, and CEO, will present a poster on Tuesday, February 8, 11:30am- 12:30pm. Poster title: Artificial Intelligence Augmented Multiplexed Cardiomyopathy and Proarrhythmia in vitro Assay of Stem Cell Cardiomyocytes for Early Drug Development
2021
November 4, 2021
Video: Kara L. Gordon, Ph.D., Vala’s Director of Neurobiology, spoke in an Elixirgen Scientific webinar, highlighting Vala’s innovations using hiPSCs in CNS drug discovery and neurotoxicity screening, including imaging using KIC® and image analysis using CyteSeer®. Watch the webinar to learn more about the latest applications of Vala’s technology to study HIV antiretroviral neurotoxicity. Read a summary of the webinar here.
2020
OCTOBER 15, 2020
Video: Paul Burridge, PhD, assistant professor of Pharmacology at Northwestern University, uses Vala’s KIC® platform to study how a patient’s genetics cause negative responses such as cardiotoxicity to chemotherapy agents.
SEPTEMBER 14, 2020
New Publication: Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity
SEPTEMBER 8, 2020
New Publication: iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy
JULY 21, 2020
New Publication: Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes
JANUARY 28, 2020
New Publication: Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence